Table 5 Management and outcomes of ARDS patients with (Aspergillus +) or without (Aspergillus −) one or more respiratory tract sample positive for Aspergillus spp.
All (n = 423) | Aspergillus − (n = 388) | Aspergillus + (n = 35) | p value | |
|---|---|---|---|---|
Microbiological examinations | ||||
Number of endobronchial samples | 4.0 (2.0–7.0) | 3.5 (2.0–7.0) | 4.5 (2.7–9.2) | 0.019 |
Including BAL | 211 (48) | 181 (45) | 30 (86) | <0.0001 |
Duration of ICU stay (days) | 12 (6–22) | 12 (6–22) | 14 (7–35) | 0.14 |
Ventilator-free days at day 28 (days) | 0 (0–17) | 0 (0–22) | 0 (0–16) | 0.19 |
Ventilator-acquired pneumonia | 146 (35) | 135 (35) | 11 (31) | 0.85 |
Treatment | ||||
Prone position | 169 (40) | 153 (40) | 16 (46) | 0.48 |
Nitric oxide inhalation | 117 (28) | 108 (28) | 9 (26) | 0.85 |
Paralyzing agents | 380 (92) | 348 (92) | 32 (91) | >0.99 |
ECMO | 21 (5) | 18 (5) | 3 (9) | 0.40 |
Shock | 350 (83) | 321 (83) | 29 (83) | >0.99 |
Renal replacement therapy | 122 (29) | 105 (27) | 17 (49) | 0.011 |
Corticosteroids | ||||
“Stress-dose” steroidsa | 144 (34) | 134 (34) | 10 (29) | 0.58 |
“High-dose” steroidsb | 96 (23) | 84 (22) | 12 (34) | 0.094 |
In-ICU mortality | 209 (50) | 188 (48) | 21 (60) | 0.22 |